Published on
May 6, 2025
Dr Harding on the FDA Approval of Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC
"What was important about this study [was that], after approximately 1 year, we saw a separation of the curves; at 24 and 36 months, [respectively], we saw 49% and 38% of patients alive [in the ipilimumab-plus-nivolumab arm]. This [regimen] shows …
Source:
OncLive
-
Pending
